An economic evaluation of adaptive e-learning devices to promote weight loss via dietary change for people with obesity. by Miners, Alec et al.
Miners, A; Harris, J; Felix, L; Murray, E; Michie, S; Edwards, P
(2012) An economic evaluation of adaptive e-learning devices to pro-
mote weight loss via dietary change for people with obesity. BMC
Health Serv Res, 12. p. 190. ISSN 1472-6963
Downloaded from: http://researchonline.lshtm.ac.uk/251182/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution http://creativecommons.org/licenses/by/2.5/
RESEARCH ARTICLE Open Access
An economic evaluation of adaptive e-learning
devices to promote weight loss via dietary
change for people with obesity
Alec Miners1*, Jody Harris2, Lambert Felix2, Elizabeth Murray3, Susan Michie4 and Phil Edwards2
Abstract
Background: The prevalence of obesity is over 25 % in many developed countries. Obesity is strongly associated
with an increased risk of fatal and chronic conditions such as cardiovascular disease and type 2 diabetes. Therefore
it has become a major public health concern for many economies. E-learning devices are a relatively novel
approach to promoting dietary change. The new generation of devices are ‘adaptive’ and use interactive electronic
media to facilitate teaching and learning. E-Learning has grown out of recent developments in information and
communication technology, such as the Internet, interactive computer programmes, interactive television and
mobile phones. The aim of this study is to assess the cost-effectiveness of e-learning devices as a method of
promoting weight loss via dietary change.
Methods: An economic evaluation was performed using decision modelling techniques. Outcomes were expressed
in terms of Quality-Adjusted Life-Years (QALYs) and costs were estimated from a health services perspective. All
parameter estimates were derived from the literature. A systematic review was undertaken to derive the estimate of
relative treatment effect.
Results: The base case results from the e-Learning Economic Evaluation Model (e-LEEM) suggested that the
incremental cost-effectiveness ratio was approximately £102,000 per Quality-Adjusted Life-Year (QALY) compared to
conventional care. This finding was robust to most alternative assumptions, except a much lower fixed cost of
providing e-learning devices. Expected value of perfect information (EVPI) analysis showed that while the individual
level EVPI was arguably negligible, the population level value was between £37 M and £170 M at a willingness to
pay between £20,000 to £30,000 per additional QALY.
Conclusion: The current economic evidence base suggests that e-learning devices for managing the weight of
obese individuals are unlikely to be cost-effective unless their fixed costs are much lower than estimated or future
devices prove to be much more effective.
Keywords: Economic evaluation, e-learning, cost-utility analysis, obesity and weight management.
Background
According to recent Organisation for Economic Co-
operation and Development (OCED) data, the prevalence
of obesity has increased to almost 25 % in countries such
as England, Canada, Ireland and Australia and to over
30 % in Mexico and the US [1]. Obesity is associated with
a higher risk of many diseases, including cardiovascular
disease and type 2 diabetes [2-5]. It is also associated with
significant costs to the health care- and other sectors. Un-
surprisingly therefore, designing and delivering effective
weight management interventions has become a priority
in many countries and a focus for many public health pro-
grammes [5,6].
Interventions to change dietary behaviour are an im-
portant method of tackling obesity [7-9]. Specifically,
interventions designed to modify or replace diets high in
saturated fats and sodium with those containing more
fruit, vegetables and lower saturated fats. Indeed the
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WHO reports that the consumption of up to 600 g per
day of fruit and vegetables could reduce the total world-
wide burden of disease by 1.8 %, and reduce the burden
of ischaemic heart disease and ischaemic stroke by 31 %
and 19 % respectively [10].
A new and evolving area in the promotion of dietary be-
havioural change is ‘e-Learning’, the use of interactive elec-
tronic media to facilitate teaching and learning on a range
of issues including health. E-Learning devices (e-LDs) have
grown out of recent developments in information and
communication technology, such as the Internet, inter-
active computer programmes, interactive television, and
mobile phones [11-15]. So-called ‘second and third gener-
ation’ e-Learning interventions use ‘adaptive’ interactive
technology delivered on computers and portable devices,
such as mobile phones to produce iterative, interactive
and more immediate feedback [16]. Moreover, they are
rapidly becoming more accessible to the general popula-
tion (e.g., an estimated 70 % of the population in the UK
has access to the internet and this percentage is likely to
continue to grow [17]). The high level of accessibility,
combined with emerging advances in computer processing
power, data transmission and data storage, makes inter-
active e-LDs a potentially powerful and cost-effective
medium for improving dietary behaviour and ultimately
health [18-20]. However, while the general conclusion
from three systematic reviews is that they show some
promise in terms of dietary behaviour change [16,21,22],
and a fourth suggests some encouragement in terms of
weight loss [23], a number of important uncertainties re-
main. For example, the most recent review included stud-
ies published up to 2008 [16], they were restrictive in
terms of patient entry criteria and, importantly, none
assessed cost-effectiveness. The latter point is the focus of
this study.
Methods
Decision problem and model basics
An economic decision model was built, referred to as
the e-Learning Economic Evaluation Model (e-LEEM),
to assess the cost-effective of the e-LDs. The model con-
sists of a cost-utility analysis (CUA), with health out-
comes expressed as quality-adjusted life-years (QALYs).
Costs were assessed from a UK health services perspec-
tive, and expressed in 2009 prices. In all scenarios, the
model was run until all patients died, implying a lifetime
horizon for the analysis. All future costs and QALYs
were discounted at 3.5 % per annum.
Defining how an e-LD is used, and therefore its asso-
ciated costs and outcomes, is difficult because they are
idiosyncratic in terms of design, platform base, not all are
commercially available and they and their use are often
poorly described in the clinical trials. Thus, for the pur-
pose of the economic evaluation a single hypothetical/
generic package has been defined broadly reflecting the
design and cost of an internet-based intervention evalu-
ated in McConnon et al. [24] as it was a well described
contemporary UK-based randomised controlled trial.
There are a number of possible comparator interven-
tions for e-LDs, indeed weight management interven-
tions are rarely used in isolation as results from the
systematic review suggest [25]. For this reason, and to
be practical, a generic ‘conventional care’ arm was speci-
fied as the comparator intervention, implying an inter-
vention that could contain a number of interventions
such as generic dietary information and/or exercise but
excluding interventions based on e-LDs or pharmaco-
logical treatment. The latter was included as a third
treatment option in a sensitivity analysis in an attempt
to put the results into a broader context. Note however,
that the estimate of relative clinical effect was not based
on formal indirect or mixed treatment comparisons.
A number of different modelling approaches were
considered. The decision was made to use a discrete
event simulation (DES) so that the likelihood of future
clinical events and associated costs could be directly
linked to individuals’ current health. Simulations were
based on 1,000 outer (second order or probabilistic)
simulations and 1,000 inner (first-order or micro) simu-
lations. EVPI calculations were also undertaken based
on a further 1,000 third-order simulations. The model
was built in TreeAge Pro 2009 [26].
The decision problem
Although e-LDs can be used to prevent obesity and as a
means of managing individuals who are already consid-
ered obese, it was understood that they are most likely
to be used in the latter scenario. Exact patient starting
characteristics were changed according to the model run
(Table 1) so that issues of patient heterogeneity could be
assessed, but in all instances, individuals had body-mass
indexes (BMIs) of at least 30 kg/m2 with the aim of re-
ducing weight or modifying further increases. Unless
otherwise stated, all individuals were assumed to be aged
50 years. All individuals were assumed to receive treat-
ment with either an e-LD or CC for 12 months, or until
they developed a disease (type 2 diabetes or cardiovascu-
lar disease), died or dropped-out from treatment, which-
ever event occurred first (Figure 1). A ‘minimising the
time to the next event’ approach was used to select the
sequence of subsequent (competing) events, given rele-
vant life-tables and risk equations. BMI was chosen as
the main model ‘driver’. That is weight change, should it
occur, was transformed into a BMI, which in turn
affected the time to future events. This meant that, all
else remaining equal, the time to developing cardiovas-
cular disease and type 2 diabetes was shorter in indivi-
duals with relatively high BMIs compared with
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individuals with lower BMIs. The natural history of dis-
ease in terms of BMI change was also modelled, mean-
ing that as people aged, mean BMI increased, as did the
likelihood of disease and death due to obesity. Addition-
ally, the risk equations were linked so, for example, indi-
viduals with type 2 diabetes were at increased risk of
developing cardiovascular disease compared to those
without it.
Estimating time to events and natural history
The time to death was calculated using a life-table ap-
proach, as outlined by Barton et al. [27] [28]. In addition
to this, 33 % [29] of patients who developed cardiovascular
disease (CVD) were assumed to die immediately once the
event had occurred. All deaths from T2D were considered
to be attributable to cardiac problems, thus they were not
independently modelled. These approaches were used in
the base case to avoid the possibility of double counting
occurrences of death, thus it is arguably conservative. The
QRISK2 [30] algorithm was used to predict the risk of
CVD. Two T2D risk equations were identified [31] [32].
While an arbitrary decision was made to use the Stern
equation, the Lindström model was used in a sensitivity
analysis.
While receiving treatment with either an e-LD or CC,
the baseline annual bodyweight was assumed to change
in line with results from a recently reported UK-based
RCT [kg ~N −1.9, 0.63] [24]. Following treatment
cessation, the natural history of BMI change was mod-
elled using evidence cited in the 2005 NICE Obesity
Guideline [33]. Specifically Fine et al., [34] state that the
mean increase in weight over 4 years is 1 kg per year.
The Guideline also states that this finding is consistent
with the findings of Heitmann et al. [35] who performed
a retrospective semi-longitudinal study to determine the
pattern of weight changes over 11 years in a Danish
population that became overweight in adulthood. Thus,
all patients were assumed to put on an average of 1 kg
per year independently of initial BMI levels.
Weight gain was converted into an increased BMI by as-
suming men were on average 1.75 ms tall whereas women
were 1.62 ms tall [36]. This is equivalent to a 0.33 and a
0.38 unit increase in BMI respectively, per 1 kg increase in
weight [BMI=weight (kg)/height2 (m)] [37]. This meant,
for example, that it would take an average of 0.31 years
(0.1/0.33) for a man’s BMI to increase by 0.1 kg/m2.
High attrition rates are a defining feature of weight loss/
preventing weight gain interventions. Therefore the prob-
ability that individuals stopped treatment before 12 months,
for reasons other than developing disease or death, was
included. The Turnin 2001 RCT was used to estimate the
base case probability of drop out, although this value was
altered in a sensitivity analysis. The results showed that
179/557 participants were lost to follow-up over the
12 month period. Differences in attrition rates between the
e-LD and CC treatment options were judged to be negli-
gible and were not included in the model [25].
Estimating relative intervention effect
Relative treatment effects were estimated using results
from a systematic review and meta-analysis [25]. In brief,
interventions were included in the review if they con-
tained RCTs of interactive computer software pro-
grammes that tailored output according to user input, in
adolescents or adults, did not include any human
Table 1 Starting characteristics for the base case analyses
Scenario A B C D E F G H
Characteristic
BMI 30 30 33 30 33 35 35 30
Sex Male Male Male Female Male Female Male Female
Smoker No Yes No No Yes Yes Yes Yes
T2D No No No No No No Yes No
Figure 1 Model schematic.
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interaction (eg. motivational telephone calls) where the
focus was on promoting dietary change. In all, 43 eligible
RCTs were identified, of which 9 (33 %) reported mean
BMI at the study end with standard deviations [25]. Ran-
dom effects meta-analysis suggested a non-statistically
significant (p = 0.69) weighted mean difference in favour
of the e-LDs [N~−0.12, 0.29] (Figure 2). There was evi-
dence to suggest estimates of effect did not differ
according to whether follow-up was earlier (within
3 months) or later (p = 0.59), if they included partici-
pants who were overweight (p = 0.58), whether the stud-
ies aimed to maintain or reduce BMI (p = 0.91) or
whether interventions included a physical activity com-
ponent (p = 0.91).
The cost-effectiveness of orlistat was also estimated in
a single sensitivity analysis. Orlistat’s mean annual effect
was estimated to be a loss of 3.46 kg, as reported by a
review of three RCTs [38].
Costs
Costs were broadly divided into two types: those asso-
ciated with specific events, and those relating to the ini-
tial 12 months of treatment (Table 1).
All costs were inflated to 2009 prices using the Hos-
pital and Community Health Services Index [39]. The
costs of CVD were taken from Warren et al., [40] and
were reported as one-off costs for fatal, non-fatal events
and an annual cost for survivors. No other costs asso-
ciated specifically with CVD were included. The annual
cost of diagnosed T2D was taken from Ara [41]. The
cost included 2 general practitioner visits per year, a spe-
cialist nurse visit, drug treatment for high blood pres-
sure, statin therapy and treatment with metformin. The
annual costs of CC and those associated with e-learning
devices were taken from a UK-based RCT of web-based
support package [24]. The costs for both interventions
included resources such as drug costs and health care
visits and slimming clubs. The main difference between
the two was that the internet-based support package
included an additional fixed cost per patient of £854 per
annum for the actual web-based support (meaning this
cost was applied per patient irrespective of how long
their treatment lasted in the base case). The yearly cost
of orlistat treatment was assumed to be £415 (based on
120 mg treatment 3 times per day, at a unit price per pill
of £0.38 [£32.27/84]), plus the cost of 5 GP visits (£35
per visit).
Utilities
All utility values were estimated from a single large UK
study that assessed the relationship between BMI, other
health-related issues and EQ-5D utility scores (Table 2)
[42]. A maximum of two long-standing illnesses were
permitted, representing the possibility of developing
CVD and T2D.
Results
The base case results are shown in Table 3 for a number
of different patient starting characteristics. Although the
absolute costs and QALYs vary across the scenarios, in
Overall  (I-squared = 0.0%, p = 0.920)
Blanson Henkemans (2009)
Shapiro (2007)
Turnin (2001)
Low (2006)
Jones (2008)
Gow (2009)
Jacobi (2007)
Zabinski (2001)
ID
Svetkey (2008)
Study
-0.12 (-0.68, 0.45)
-0.38 (-1.98, 1.22)
1.60 (-5.70, 8.90)
-0.60 (-1.99, 0.79)
-0.40 (-2.51, 1.71)
-1.41 (-3.87, 1.05)
0.30 (-1.98, 2.58)
0.30 (-0.81, 1.41)
-0.40 (-2.20, 1.40)
WMD (95% CI)
0.40 (-0.97, 1.77)
decrease with e-Learning  increase with e-Learning 
0-4 -2 2 4
Effect on mean BMI
Figure 2 Forest plot of treatment effect on mean BMI (kg/m2.
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each instance the incremental health gains were small, as
indicated by the fact very few additional cases of T2D or
CVD were averted. The lowest reported ICER was ap-
proximately £102,000 per additional QALY (scenario A).
Scenarios containing women were associated with lower
QALYs compared with men (e.g. scenario D compared
with A) because lower rates and time spent with CVD
were more than offset by higher rates and time spent with
T2D. The cost-effectiveness acceptability frontier for sce-
nario A (Figure 3) shows that up to about £200,000 per
additional QALY, CC is the preferred option, but even
after this point, there is a high degree of uncertainty
around e-LD being the most cost-effective option.
Sensitivity analysis
A number of one-way sensitivity analyses were per-
formed. Arguably the most important in terms of large
changes to the ICER were the fixed costs associated with
the e-learning devices, the relative treatment effect, the
rate at which health outcomes were discounted and the
duration of treatment effect (Table 5).
When orlistat was included as a comparator, it domi-
nated e-LD. Against CC, orlistat cost almost £6,000 per
additional QALY.
Expected value of perfect information (EVPI) analysis
The per person EVPI was £11 rising to £506 at willing-
ness’s to pay (WTP) for an additional QALY of £0 and
£100,000 respectively. The population EVPI was esti-
mated by assuming 2 and 10-year intervals, a 3.5 % an-
nual discount rate and annual UK obesity incidence of
308,000 [37]. The corresponding population EVPI value
was arguably large at all positive willingness’s to pay
Table 2 Description of costs
Description Mean Value Distribution^ Source
CVD fatal event £3,058 Gamma (9, 0.00295) Warren* [40]
CVD non-fatal event £3,648 Gamma (9, 0.002469) Warren* [40]
Annual cost of non-fatal CVD event £876 Gamma (9, 0.010309) Warren* [40]
Annual cost of T2D £724 Gamma (9, 0.0125) Ara [41], NICE Guideline* [33]
Annual cost attributable to orlistat £715 N/A BNF [43], Foxcroft [38]
Annual cost of e-leaning device £140 (SE £234) Gamma (0.3549, 0.002535) McConnon$ [24]
Fixed cost of e-learning device £854 N/A McConnon$ [24]
Annual cost of conventional care £226 (SE £329) Gamma (0.479, 0.002088) McConnon$ [24]
*Indicates that mean values were derived from this source but measures of variance were not reported. In these instances, standard errors were based on one
third of the mean value.
$An extended report relating to the published economic was supplied by the authors.
^parameterised as required in TreeAge Pro 2009, Gamma~ (α, λ).
Table 3 Base case results (see Table 4 for patient starting
characteristics
Scenario Intervention Cost (£) QALYs ICER (£)
A CC 4,884 12.527 -
e-LD 5,646 12.534 102,112
B CC 5,364 12.093 -
e-LD 6,129 12.100 121,856
C CC 5,340 12.196 -
e-LD 6,088 12.200 184,962
D CC 4,035 11.703 -
e-LD 4,732 11.708 125,891
E CC 5,810 11.838 -
e-LD 6,566 11.844 150,865
F CC 5,201 11.209 -
e-LD 5,902 11.214 151,142
G CC 15,014 10.910 -
e-LD 15,789 10.911 232,911
H CC 4,469 11.500 -
e-LD 5,186 11.506 112,628
CC, conventional care; e-LD, e-learning device; QALYs, quality-adjusted life-
years; ICER, incremental cost-effectiveness ratio.
Figure 3 Cost-effectiveness acceptability frontier (CEAF)
relating to scenario A.
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(Figure 4). For example the 2-year population results for
the complete model was almost £33 million at a WTP of
£20,000.
A single expected value of information analysis for
parameters (EVPPI) was undertaken on the relative
treatment effect (weighted mean difference) associated
with two treatment options. The results suggest that at a
willingness to pay of £20,000 to £30,000 per additional
QALY, the maximum value of conducting a further RCT
was between £37 M and £170 M. However, these figures
reduced to between £8 M and £36 M if the time horizon
was reduced to 2 years
Discussion
The aim of this study was to assess the cost-effectiveness
of e-learning devices (e-LDs) compared with conven-
tional care (CC) in people with obesity. An economic
evaluation based on discrete event simulation techniques
was used to synthesise data from the published literature
together with results from a systematic review and
meta-analysis of RCT evidence on the impact of treat-
ment on BMI.
The model results suggest that under most circum-
stances, e-LDs are unlikely to be cost-effective at any
reasonable willingness-to-pay threshold. Mainly because
of the fixed costs of installing the devices coupled with a
negligible impact on BMI. Only when the fixed cost of
the e-LD was removed, or substantially lowered, did e-
learning devices appear to be cost-effective.
The fixed costs associated with the e-LDs were diffi-
cult to assess. Largely because most of the published
clinical evaluations did not report resource use/cost
data, they are heterogeneous in nature and it was un-
clear whether any were commercially available (and
therefore had an associated user fee). For these reasons,
the fixed cost of the e-LDs, was taken directly from the
trial by McConnon - an internet-based intervention. The
associated costs comprised of the development and run-
ning costs of the website over the 12 month study
period. An economic evaluation was performed along-
side the RCT, and it too concluded that the e-LD was
unlikely to be cost-effective largely because of the fixed
cost. However, it is unclear whether all e-LDs have an
associated fixed cost. Second, assuming they do, fixed
costs are likely to decline as the number of users
increases meaning they could be substantially lower than
the mean value assumed in this analysis. Third, even if
Table 5 Sensitivity analysis on scenario A patient
characteristics
Parameter CC e-LD
Costs (£) QALYs Costs (£) QALYs ICER (£)
Doubling the time to a 0.1
BMI increase after
treatment stops
4,545 12.972 5,302 12.978 122,125
£0 initial cost for
e-learning devices
4,903 12.475 4,845 12.483 Dom
Lindstrom T2D risk
equation [32]
4,248 12.812 5,608 12.818 124,813
Starting age of 30 years 5,065 17.976 5,820 17.986 74,151
Starting age of 60 years 4,577 9.749 5,347 9.754 118,741
Using estimate of relative
treatment effect from Turnin
(N~−0.6, 0.71) [44]
4,999 12.802 5,704 12.837 20,053
Doubling all T2D related costs 6,819 12.416 7,561 12.435 83,306
Doubling all CVD related costs 7,704 12.507 8,458 12.513 100,480
Doubling the cost of CC 5,115 12.482 5,706 12.488 86,323
0 % discount rate for
health benefits
4,943 19.325 5,699 19.338 58,869
Halving the attrition rate
for both treatments
4,871 12.799 5,662 17.897 84,483
Treatment for 24 months 5,600 12.806 5,719 12.817 64,487
Dom, e-learning is ‘dominant’; *59 % probability e-LD is cost-effective at
£30,000 per additional QALY; CC, conventional care; e-LDs; e-learning devices.
Figure 4 EVPI and a single EVPPI analysis based on scenario A
assumptions, and an incident obese population of 308,000
people every year for 2 and 10 years, discounted at 3.5 % per
annum.
Table 4 Relationship between independent variables and
EQ-5D utility scores, Macran et al. [42]
BMI group
(kg/m2)
Coefficient Age group
(years)
Coefficient No.
of LSIs*
Coefficient
<21 −0.02 18-24 0 0 0
21-25 0 25-34 0.0005 1 −0.115
26-30 −0.02 35-44 −0.01 2 −0.196
31-39 −0.04 45-54 −0.02
>39 −0.06 55-64 −0.04
65-74 −0.04
>75 −0.08
*LSIs, Long standing illnesses.
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the fixed cost was zero, it is unclear whether commercial
programme developers would charge a fee for using the
programme, how much it would be and how frequently
it would be charged.
The choice of comparator programme(s) is an import-
ant design decision for any economic evaluation. Here
the choice was ‘conventional care’ as delivered by health
care professionals, as the control arms in the systematic
review tended to use a mix of interventions. For ex-
ample, most of the trials that focussed on dietary change
were not particularly explicit as to what advice was given
(eg. choice of diet) or who provided it (eg. a physician or
nurse). This is important because it is possible that dif-
ferent approaches may be more or less cost-effective
compared with each other, and (implicitly) averaging
them as is the case here, could be misleading from an
incremental perspective. Of equal importance, CC, how-
ever delivered, is not the only method of reducing
weight. For example, it is possible to promote exercise,
to use drug treatments such as orlistat or to use combi-
nations of these approaches. Although the analysis con-
taining orlistat was only crude in so much that it was
not based on formal indirect treatment comparisons, it
does illustrate the point that even if e-LDs were consid-
ered cost-effective compared with CC, they might not be
compared with other treatments.
A number of economic evaluations of web-based inter-
ventions to promote weight loss have previously been
published [24,45-47]. McConnon et al. [24] concluded that
it cost about £40,000 per additional QALY if an internet
programme replaced usual care, while the two other stud-
ies reported ICERs nearer US$5,000 to $7,000 per life-year
gained. While these results are different to ours, there are
a number of possible explanations. First, our study focused
purely on e-learning devices. The other studies were not
so restrictive in terms of the intervention specifics. Indeed
the interventions evaluated by Krukowski [46] and Hersey
[47] included an element of interaction with other
patients, individual/group coaching sessions and telephone
support, they were not e-learning devices. Second, our es-
timate of intervention effect was based on the results from
a systematic review of 43 RCTs whereas the studies by
McConnon and Krukowski were based on the results from
single trials. Third, the study by Krukowski assumed in
the base case that weight loss could not be regained, an as-
sumption we consider to be unrealistic. Lastly, our study
assessed the cost-effectiveness in people who were already
considered to be obese. This is was an explicit criterion in
the studies by McConnon and Hersey, but not in the
evaluation by Krukowski. Indeed, the latter was said to
have been performed in individuals who were highly edu-
cated, but few other details are provided. Therefore, while
we have concluded that in our opinion e-LDs to promote
dietary change and weight loss are unlikely to be cost-
effective in obese populations, this conclusion should not
necessarily be generalised to all web-based weight man-
agement interventions or to all population groups
There are undoubtedly a number of other limitations
with the evidence used in the model. First, the QRISK2
risk equation is designed to assess the probability of
developing primary CVD-events. Thus, the model takes
does not take into account the possibility that indivi-
duals who survive one CVD event are more likely to ex-
perience another. However, it is unlikely that this would
have a major bearing on the results given the negligible
treatment effects.
The CVD and T2D risk equations take into account
risk factors such as systolic blood pressure and choles-
terol levels in addition to BMI. While the trials rarely
reported changes in these risk factors, a more sophisti-
cated modelling approach could take into account their
likely correlations.
Potentially counter intuitive results were produced in
a number of scenarios. For example, when the costs of
T2D and CVD were increased, the ICER associated with
e-learning also increased. This is because people treated
with e-learning devices live longer on average with these
conditions, even though they are less likely to develop
them in the first instance. The net result is an increase
in the incremental cost and the associated ICER. Such
seemingly counter intuitive results were also reported in
the NICE Obesity Guideline, along with a similar ex-
planation [33].
The EVPI analysis suggested that the value of further
research was arguably large, even with a 2 year horizon;
e-based technologies are likely to have relatively short
life-cycles. This is because despite the evidence of a rela-
tively small clinical effect on BMI, the e-LDs are rela-
tively cheap and the number of obese people is high
compared with many other conditions
Conclusion
The e-LEEM model was built to assess the cost-
effectiveness of e-learning devices compared to CC for
people with obesity, as methods of promoting healthier
eating and weight loss. The model contains a number of
assumptions and necessarily draws on evidence from a
number of different sources. The results suggest that e-
LDs are unlikely to be cost-effective unless they have
much lower fixed costs than estimated for this analysis
or future designs prove to be much more effective. Des-
pite this, the value of further RCT-based research is
high, although researchers are strongly encouraged to
provide fuller descriptions of the evaluated technologies.
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